You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 9,119,781


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,119,781 protect, and when does it expire?

Patent 9,119,781 protects ENSTILAR and is included in one NDA.

Protection for ENSTILAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in twenty-five countries.

Summary for Patent: 9,119,781
Title:Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative and a corticosteroid, and its use in the treatment of dermal diseases and conditions. The spray comprises especially a propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethyl ether or a mixture thereof and further a pharmaceutically acceptable lipid carrier solubilised or suspended in said propellant.
Inventor(s): Lind; Marianne (Bagsv.ae butted.rd, DK), Rasmussen; Gritt (Virum, DK), Sonne; Mette Rydahl (Brondby Strand, DK), Hansen; Jens (Virum, DK), Petersson; Karsten (Ballerup, DK)
Assignee: LEO PHARMA A/S (Ballerup, DK)
Application Number:13/703,214
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,119,781
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 9,119,781: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, businesses, and legal professionals. This article will delve into the details of United States Patent 9,119,781, exploring its claims, the patent landscape, and relevant legal and procedural aspects.

Overview of the Patent

United States Patent 9,119,781, hereafter referred to as the '781 patent, was granted to its inventors on August 25, 2015. To analyze this patent, one must first identify its key components, including the title, abstract, and claims.

Title and Abstract

The title of the patent provides a brief description of the invention, while the abstract offers a more detailed summary. These elements are essential for understanding the patent's subject matter and scope.

Claims Analysis

Independent Claims

Independent claims define the broadest scope of the invention and are typically the most critical claims in a patent. They stand alone and do not depend on other claims. Analyzing these claims helps in understanding the core aspects of the invention.

Dependent Claims

Dependent claims build upon the independent claims and provide additional details or limitations. They are narrower in scope and often describe specific embodiments or variations of the invention.

Claim Construction

Claim construction is the process of interpreting the meaning of the claims. This involves understanding the language used, the context, and any relevant definitions or explanations provided in the specification. The USPTO and courts often use the "plain and ordinary meaning" rule to interpret claim terms[4].

Patent Landscape

Prior Art and Citations

The patent landscape includes prior art and citations that were considered during the patent examination process. Tools like the USPTO's Patent Public Search and the Common Citation Document (CCD) application can help identify relevant prior art and citations[4].

Related Patents and Family Members

Identifying related patents and family members is crucial. This includes continuations, continuations-in-part, and divisional applications. For example, in the case of In re Cellect, multiple patents within the same family were analyzed for obviousness-type double patenting (ODP)[1].

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine that prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of Patent Term Adjustment (PTA) or other factors. This doctrine is particularly relevant when dealing with patent families and continuations[1].

Patent Term Adjustment (PTA) and Terminal Disclaimers

PTA can extend the term of a patent due to USPTO delays during prosecution. However, terminal disclaimers, which are often used to overcome ODP rejections, can affect the patent term. The Board has reasoned that a grant of PTA should not extend the term of a patent past the date of a terminal disclaimer[1].

Legal and Procedural Aspects

Patent Examination Process

The patent examination process involves several stages, including filing, searching, and examination. Tools like the Patent Examination Data System (PEDS) provide insights into the examination process and can help in understanding the patent's history[4].

Reexamination and Appeal

Patents can be subject to reexamination, which may lead to the invalidation of claims. In cases like In re Cellect, the Board sustained the examiner’s determinations that the asserted claims were unpatentable under ODP. Understanding the appeal process and the role of the Patent Trial and Appeal Board (PTAB) is essential[1].

Economic and Strategic Implications

Patent Scope and Value

The scope of a patent, as defined by its claims, directly impacts its value. Broader claims can provide greater protection but may be more susceptible to challenges. The USPTO's Patent Claims Research Dataset can provide insights into claim scope and patent value[3].

Licensing and Enforcement

The claims and scope of a patent also influence licensing and enforcement strategies. Clear and well-defined claims can facilitate licensing agreements and strengthen enforcement positions.

International Patent Landscape

Global Dossier and International Search

The Global Dossier service and international patent databases like those from the European Patent Office (EPO), Japan Patent Office (JPO), and World Intellectual Property Organization (WIPO) can help in understanding the global patent landscape for similar inventions[4].

Key Takeaways

  • Claims Analysis: Understanding independent and dependent claims is crucial for defining the invention's scope.
  • Patent Landscape: Identifying prior art, related patents, and family members is essential for navigating the patent landscape.
  • ODP and PTA: Obviousness-type double patenting and Patent Term Adjustment can significantly impact the patent term and validity.
  • Legal and Procedural Aspects: Familiarity with the patent examination process, reexamination, and appeal procedures is vital.
  • Economic and Strategic Implications: The scope and value of a patent influence its economic and strategic significance.

FAQs

What is the significance of independent claims in a patent?

Independent claims define the broadest scope of the invention and are typically the most critical claims in a patent.

How does ODP affect patent validity?

ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of PTA or other factors.

What is the role of the Patent Trial and Appeal Board (PTAB) in patent reexamination?

The PTAB reviews and decides on the validity of patent claims during reexamination proceedings, sustaining or reversing the examiner’s determinations.

How can the Global Dossier service help in patent research?

The Global Dossier service provides access to the file histories of related applications from participating IP Offices, allowing users to see the patent family for a specific application and related data.

What is the impact of Patent Term Adjustment (PTA) on the patent term?

PTA can extend the term of a patent due to USPTO delays during prosecution, but it does not extend the term past the date of a terminal disclaimer.

Sources

  1. In re Cellect, LLC, United States Court of Appeals for the Federal Circuit, 2023.
  2. U.S. Patent and Trademark Office (USPTO), USAGov.
  3. Patent Claims Research Dataset, USPTO.
  4. Search for patents, USPTO.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,119,781

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Leo Pharma As ENSTILAR betamethasone dipropionate; calcipotriene AEROSOL, FOAM;TOPICAL 207589-001 Oct 16, 2015 AB RX Yes Yes 9,119,781*PED ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,119,781

PCT Information
PCT FiledJune 10, 2011PCT Application Number:PCT/DK2011/000060
PCT Publication Date:December 15, 2011PCT Publication Number: WO2011/154004

International Family Members for US Patent 9,119,781

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011264198 ⤷  Subscribe
Brazil 112012030653 ⤷  Subscribe
Canada 2800181 ⤷  Subscribe
China 102939078 ⤷  Subscribe
Cyprus 1115991 ⤷  Subscribe
Denmark 2579852 ⤷  Subscribe
European Patent Office 2579852 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.